January 27, 2021
Weil is advising Sanofi in its pending $1.45 billion acquisition of Kymab, Ltd., a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. The transaction is expected to close in the first half of 2021, subject to customary closing conditions.
The Weil team advising Sanofi is led by Mergers & Acquisitions partners Michael J. Aiello and Michael Francies and includes Mergers & Acquisitions associates Jack Gray, Iliana Ivanova, Michael Grant and Tom Tsatsis and Rhys Williams. The team also includes Banking & Finance partners Reena Gogna and Morgan Bale; Banking & Finance counsel Ben Burton; Tax partners Jenny Doak and Graham Magill; Tax associate Akash Mehta; Executive Compensation & Benefits Head Paul Wessel; Executive Compensation & Benefits counsel Craig Olshan; Technology & IP Transactions Head Michael Epstein; Technology & IP Transactions partner Barry Fishley; Technology & IP Transactions counsel Caroline Geiger and Briony Pollard; Technology & IP Transactions associates Caleb Small and Madeline Koo; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; Antitrust associates Vivian Wang; and Employment counsel Ivor Gwilliams.